KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Other Operating Expenses (2018 - 2025)

Emergent BioSolutions (EBS) has 10 years of Other Operating Expenses data on record, last reported at $12.2 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $12.2 million; the TTM value through Sep 2025 reached -$12.2 million, down 150.21%, while the annual FY2024 figure was $24.3 million, 67.25% down from the prior year.
  • Other Operating Expenses reached $12.2 million in Q4 2025 per EBS's latest filing, up from -$12.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $305.2 million in Q4 2021 and bottomed at -$40.0 million in Q2 2024.
  • Average Other Operating Expenses over 5 years is $121.2 million, with a median of $114.2 million recorded in 2021.
  • The widest YoY moves for Other Operating Expenses: up 9285.71% in 2024, down 153.4% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $305.2 million in 2021, then fell by 20.25% to $243.4 million in 2022, then crashed by 100.29% to -$700000.0 in 2023, then surged by 9285.71% to $64.3 million in 2024, then tumbled by 81.03% to $12.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $12.2 million in Q4 2025, -$12.2 million in Q1 2025, and $64.3 million in Q3 2024.